News

An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.

De-escalation of treatment strategies aims to minimize toxicity while maintaining efficacy.

The days - or even weeks - spent waiting for the results of a cancer-screening test can feel like an eternity. Especially when early diagnosis and quick action are tied to better outcomes. Now, a new technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types.

Researchers show compounds based on chloroindazole reduce inflammation as well as promote neuroprotection and remyelination, improving the primary symptoms in a mouse model of multiple sclerosis.

An analysis of cervical precancers over a period of seven years showed that two strains of human papillomavirus (HPV) that have been targeted by vaccination since 2006 have declined, accounting for a smaller proportion of cervical disease, according to newly published research.

Phenotypic screening of a curated library of plant extracts has revealed a compound with neuroprotective and anti-inflammatory properties. The compound is found in a plant dubbed the "holy herb."

A new cell culture study reveals that salt leads to the formation of Th2 cells - immune cells which are active in allergic conditions such as atopic dermatitis. The team also detected elevated salt concentrations in the skin of patients with atopic dermatitis.

Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.

A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.

In a strategic search, scientists created and screened a library of 45,000 new compounds containing chemical elements of widely used immune system suppressants, and say they found one that may prevent reperfusion injury, a tissue-damaging and common complication of surgery, heart attack and stroke.